@article{d82227d01a5d4dffa00b120b5a4d373b,
title = "The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials",
abstract = "To evaluate the number needed to treat (NNT) and the number needed to harm (NNH) of the second-generation biologics abatacept, certolizumab, golimumab, rituximab, and tocilizumab in patients with established rheumatoid arthritis (RA) taking concomitant methotrexate (MTX).",
keywords = "Adult, Antibodies, Monoclonal, Antirheumatic Agents, Arthritis, Rheumatoid, Biological Agents, Databases, Bibliographic, Double-Blind Method, Female, Humans, Male, Middle Aged, Randomized Controlled Trials as Topic, Research Design, Sample Size",
author = "Kristensen, {L E} and Jakobsen, {A K} and Bartels, {E M} and P Geborek and H Bliddal and T Saxne and B Danneskiold-Sams{\o}e and R Christensen",
year = "2011",
doi = "10.3109/03009742.2010.491834",
language = "English",
volume = "40",
pages = "1--7",
journal = "Scandinavian Journal of Rheumatology",
issn = "0300-9742",
publisher = "Taylor and Francis Ltd.",
number = "1",
}